Skip to main content

Table 4 Univariate analysis of mRS at discharge

From: Baseline platelet count may predict short-term functional outcome of cerebral infarction

 

mRS0-2 (318)

mRS3-6 (67)

P-value

N

%

N

%

sex (male)

208

65.4

37

55.2

0.125

Age

67.8 ± 14.2

77.18 ± 13.4

 < 0.001

BMI

22.6 ± 3.50

22.58 ± 3.50

0.380

smoking habit

68

21.8

12

17.9

0.620

hypertension

236

74.2

53

79.1

0.441

diabetes

134

42.1

24

35.8

0.412

dyslipidemia

241

75.7

43

64.1

0.066

IHD

30

9.4

8

11.9

0.504

Af

68

21.3

26

38.8

0.004

history of CI

49

15.4

11

16.4

0.853

NIHSS ≥ 8

18

15.6

29

43.2

 < 0.001

WBC

6940 ± 2510

7761 ± 2732

0.017

Hb

13.7 ± 2.07

13.6 ± 2.22

0.649

Stroke subtype

     

SVO

48

15.0

2

2.9

0.005

LAS

36

11.3

11

16.4

0.303

CE

78

24.5

29

43.2

0.003

BAD

22

6.9

6

8.9

0.604

Pre-medication

     

CaB

92

28.9

22

32.8

0.557

ARB

75

23.5

16

23.8

0.998

ACE-I

10

3.1

6

8.9

0.042

diuretics

21

6.6

10

14.9

0.044

statins

97

30.5

13

19.4

0.075

DPP4/GLP1

52

16.3

7

10.4

0.266

anticoagulant

50

15.7

8

11.9

0.713

antiplatelet

70

22.1

16

23.8

0.748

  1. Values are expressed as the mean ± SD. Bold p-values = p < 0.2
  2. BMI body mass index, IHD ischemic heart disease, Af atrial fibrillation, history of CI history of cerebral infarction, NIHSS National Institutes of Health Stroke Scale, SVO small-vessel occlusion, LAS large-artery atherosclerosis, CE cardiogenic embolism, BAD branch atheromatous disease, CaB calcium channel blocker, ARB angiotensin II receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, DPP4 dipeptidyl peptidase 4 inhibitor, GLP1 glucagon-like peptide-1
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us